Kyowa Kirin Pharmaceutical Research, Inc.

Kyowa Kirin Pharmaceutical Research, Inc. (KKR) is a wholly owned U.S. subsidiary of Kyowa Hakko Kirin Co., Ltd. dedicated to discovering first-in- class therapeutics that address unmet medical needs and improve the health of patients. KKR serves as Kyowa Hakko Kirin’s primary drug discovery center in the United States with more than 30 research staff members working each day to discover biologics, including antibodies, in the therapeutic areas of immunology, allergy and fibrotic disease.  Since its inception, KKR has focused on open innovation through several industry–academia collaborative programs including supporting the research of La Jolla Institute for Allergy and Immunology (LJI) for more than 20 years. Industry–academia partnerships are one of KKR’s principal missions to enhance its network-based drug discovery activities.